Log in
This case study outlines the impact in generating investment in a spin-out SME and in developing a technology for clinical diagnosis based on chemistry research carried out in Bath. The research led to a spin-out company, Atlas Genetics, which has raised over £18M funding in the REF period specifically to develop the Atlas io™ platform, novel technology for rapid (<30 minute) and robust detection of infectious diseases suitable for point-of-care. The investment has created new jobs for highly skilled workers at the cutting-edge of medical diagnostics, with Atlas currently employing 36 staff. The io™ platform has been fully developed and has undergone successful clinical tests on multiple infections (based on bespoke Chemistry developed at Bath) prior to clinical trialling and rollout in Europe and the United States.
Half of all burn injuries occur in children and around 10% of children who are burnt become infected by disease-causing bacteria that can increase the likelihood of scarring and in some cases cause death. Novel wound dressing prototypes have been developed using responsive smart sensing chemistry. These provide clinical solutions and commercial opportunities, have led to the founding of the charity Healing Foundation Children's Burns Research Centre with £1.5M of funding, have influenced the work of other charities and altered attitudes and practice in clinical paediatric burn treatment. The impact has been achieved by development of the novel chemistry in partnership with clinicians and practitioners, and through extensive engagement with health professionals, well beyond normal academic reach, parents and the wider public.
Diamond's research has enhanced public understanding of the lives of French civilians during World War 2. Her work with cultural professionals, including radio and television producers, museum curators, non-academic editors and publishers, has enhanced economic prosperity in the creative sector. She has been able to integrate new ways of thinking about the period into public discourse and to extend her reach to global audiences. She has used the internet to communicate her research and her interactive website has enabled numerous individuals to gain public recognition for their stories. This co-production of historical knowledge provides an innovative way for cultural heritage to be preserved and conserved digitally.
A commercial continuous glucose sensor/monitor that provides real time data has been developed by GlySure, a venture capital funded company founded on the basis of Bath chemistry. The sensor enables Tight Glycaemic Control (TGC) for control of glucose levels in patients in Intensive Care Units (ICUs), reducing severe hypoglycaemia, glycaemic variability and the nursing burden, maximising both patient and economic benefit. This has led to (i) £13.5M investment in the company GlySure Ltd directly for development of the system based on the Bath chemistry and (ii) successful results from full clinical trials of the device, involving more than 200 ICU patients, prior to CE approval and launch in the EU.
Global Positioning System (GPS) devices are integrated into many modern electronic systems. The protection of these systems is vital to the daily operation of a nation's infrastructure and security. A new device and service for radio-frequency interference detection has been developed at Bath and is protecting GPS-reliant infrastructure from deliberate and accidental jamming. The system resulted from research into GPS signal processing. Commercial impact has resulted from the development of products and services operated internationally by a UK company. Policy impact has resulted from Ofcom's move towards making the possession of a GPS jammer illegal [text removed for publication]. Economic and societal benefit has resulted from the protection against criminal jamming, ensuring the seamless running of transportation, telecommunications and emergency services that depend on GPS.
Catalysis is a major UK industry strength and wealth generator for the UK economy. Research carried out in the group of Professor Matthew Davidson in the Department of Chemistry at the University of Bath resulted in the development of titanium and zirconium alkoxide catalysts for use in three industrial polymerisation processes and patented by the UK companies ICI Synetix and Johnson Matthey. Patents have recently also been acquired by the Indian multinational Dorf Ketal and filed by the Dutch multinational Corbion Purac. The research has resulted in the adoption of new catalysts in industry leading to increased turnover, onward dissemination and implementation of the Bath intellectual property. It has also generated £4.6M from sale of intellectual property and an increase in generated sales of new, sustainable titanium catalysts that replace heavy metals such as tin, antimony and mercury in major industrial processes. The intellectual property and process developments have been implemented globally in the poly(ethylene terephthalate) (PET) and poly(urethane) (PU) plastics markets, worth $23B and $33B, respectively, in 2010.
Space weather can adversely affect the performance of many communication and navigation systems. Research into space weather events and their mapping through our Multi-Instrument Data Analysis System (MIDAS) algorithms have highlighted the vulnerability of Global Satellite Navigation Systems (including GPS). The impact of our research has occurred in three main ways. Firstly, it has impacted on the global satellite and communications industry by enabling space-weather effects to be included in a sophisticated commercial GPS simulator. Secondly, it has impacted on UK government [text removed for publication]. Thirdly, it has engaged and informed the public about GPS and space weather.
University of Bath research has helped the National Health Service (NHS) successfully to make fundamental changes in its procurement policy, with 2.7 per cent savings on £18 billion of expenditure. The changes incorporated plurality of provision and strategic, collaborative approaches to deliver better value-for-money decisions and improve quality of life for patients. Using this framework, Audiology Services have been able to provide digital hearing aids to patients free of charge, at the same time saving £252 million on the purchasing price of the aids and cutting service costs by £45.5m annually. This approach was also applied across all NHS expenditure categories and achieved savings of around £500m on goods and services worth £18 billion a year. The research has also shaped the Department of Health's Commercial Strategy encouraging a more strategic use of network resources for the benefit of patients and taxpayers.
Atlas Genetics Ltd is a University of Bath spin-out company established in 2005 by Dr John Clarkson, a former lecturer in the Department of Biology and Biochemistry (DBB). In collaboration with DBB researchers, Atlas Genetics developed novel technology for rapid (<30 minute) and robust detection of infectious diseases at the point-of-care. Atlas Genetics has raised over £22m funding specifically to develop the Atlas ioTM detection system, which combines a patented electrochemical detection system with probes for specific micro-organisms within a small disposable cartridge. Different probe cartridges are used to detect a range of pathogens that have critical clinical importance and large-scale socio-economic significance, including Candida, methicillin resistant Staphylococcus aureus (MRSA), bacterial meningitis, and sexually transmitted diseases (STDs) Trichomonas, Chlamydia and Gonorrhoea. Candida research in DBB underpinned the specificity, sensitivity and application of the technology to clinical samples and was used in seeking capitalization for Atlas.
Atlas Genetics re-located from the University to a nearby business park and employs 35 full-time staff, some having moved from academia into the company largely thanks to the synergistic relationship with University of Bath researchers. The ioTM platform has undergone successful clinical tests on Chlamydia and Trichomonas at Johns Hopkins University, USA. The ioTM platform and Chlamydia test is scheduled for clinical trials in 2014, with roll out in Europe and the USA, pending regulatory approval, providing global reach within the $42bn in vitro diagnostics market.
Over the past 13 years the University of Bath has been leading research into low-impact bio-based construction materials, including the construction and testing of two full-scale prototype buildings: BaleHaus (2009) and HemPod (2010) built on campus. The research has directly promoted: the development and wider market acceptance of award winning low carbon construction products (ModCell® and Hemcrete®); successful delivery of award winning buildings; and the wider sector uptake of these technologies, including in a new school building in Bath. The work has directly benefited industry partners working to meet UK Government policy requirements to deliver low carbon infrastructure and benefited society through the delivery of affordable sustainable buildings.